Review
Pharmacology & Pharmacy
Alberto Chierigo, Lorenzo Ferro Desideri, Carlo Enrico Traverso, Aldo Vagge
Summary: Several approaches have been investigated to prevent myopia progression in children and teenagers, among them, topical atropine has shown promising results. However, the optimal formulation and treatment algorithm have yet to be determined. Further larger-scale studies are needed to characterize the clinical efficacy of atropine and define the optimal dosage and treatment regimen.
Article
Medicine, General & Internal
Jiahe Gan, Shi-Ming Li, Shanshan Wu, Kai Cao, Dandan Ma, Xi He, Ziyu Hua, Meng-Tian Kang, Shifei Wei, Weiling Bai, Ningli Wang
Summary: This study evaluated the efficacy and safety of atropine in slowing myopia progression and found that its efficacy is dose-dependent, with low-dose atropine showing better efficacy in a longer follow-up period.
FRONTIERS IN MEDICINE
(2022)
Article
Ophthalmology
Luyao Ye, Hannan Xu, Ya Shi, Yao Yin, Tao Yu, Yajun Peng, Shanshan Li, Jiangnan He, Jianfeng Zhu, Xun Xu
Summary: This study investigated the efficacy and safety of consecutive use of 1% and 0.01% atropine compared with 0.01% atropine alone in the treatment of myopia. The results showed that consecutive use of atropine had a better effect in slowing myopia progression than using atropine alone.
OPHTHALMOLOGY AND THERAPY
(2022)
Article
Medicine, General & Internal
William Myles, Catherine Dunlop, Sally A. McFadden
Summary: Low-dose atropine can slow the progression of myopia in children, especially in the 'slow' progression group. However, rebound occurred in three-quarters of eyes after cessation of atropine. Adverse effects were observed in 69% of patients, with dilated pupils being more common in children with blue eyes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Ophthalmology
Jost B. Jonas, Marcus Ang, Pauline Cho, Jeremy A. Guggenheim, Ming Guang He, Monica Jong, Nicola S. Logan, Maria Liu, Ian Morgan, Kyoko Ohno-Matsui, Olavi Parssinen, Serge Resnikoff, Padmaja Sankaridurg, Seang-Mei Saw, Earl L. Smith, Donald T. H. Tan, Jeffrey J. Walline, Christine F. Wildsoet, Pei-Chang Wu, Xiaoying Zhu, James S. Wolffsohn
Summary: The prevalence of myopia is increasing in East and Southeast Asia, with strategies needed to reduce its progression. Encouraging outdoor activities and using low-dose atropine eye drops are beneficial measures for reducing myopia development. Individual risk-to-benefit ratios need to be considered for different treatment options based on age, health, and lifestyle.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2021)
Article
Medicine, General & Internal
Zi-Rong Chen, Shin-Chieh Chen, Tsung-Yao Wan, Lan-Hsin Chuang, Hung-Chi Chen, Lung-Kun Yeh, Yu-Kai Kuo, Pei-Chang Wu, Yun-Wen Chen, Ing-Chou Lai, Yih-Shiou Hwang, Chun-Fu Liu
Summary: This study aimed to compare the efficacy of atropine 0.125% once every two nights (QON) and once every night (HS) in treating myopia in children. The results showed that the treatment effects of atropine 0.125% HS and QON were similar, suggesting that atropine 0.125% QON may be an alternative strategy for children who cannot tolerate the side effects of atropine 0.125% HS.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Ophthalmology
Ahnul Ha, Seong Joon Kim, Sung Ryul Shim, Young Kook Kim, Jae Ho Jung
Summary: This study compares the efficacy and safety of different concentrations of atropine for myopia control through network meta-analysis. The results show that the 1%, 0.5%, and 0.05% concentrations of atropine are ranked as the most beneficial for myopia control in terms of yearly changes in refraction and axial length. The 0.05% concentration of atropine is ranked as the most beneficial for overall myopia progression. The risk of adverse effects tends to increase with higher atropine concentrations.
Article
Multidisciplinary Sciences
Xingxue Zhu, Yuliang Wang, Yujia Liu, Chaoying Ye, Xingtao Zhou, Xiaomei Qu
Summary: This study found that the use of 0.01% atropine eye drops can effectively prevent myopia progression, but it also leads to an increase in axial length and total astigmatism in myopic Chinese children.
Review
Pharmacology & Pharmacy
Peixian Hou, Dawen Wu, Yan Nie, Hong Wei, Longqian Liu, Guoyuan Yang
Summary: The study aimed to comprehensively evaluate the efficacy and safety of different concentrations of atropine for retarding myopia progression and determine the most appropriate therapeutic concentration for clinical practice. The results showed that 0.05% atropine may be the best concentration to control myopia progression at present.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pediatrics
Weiqun Wang, Fengyan Zhang, Shiao Yu, Nana Ma, Congcong Huang, Ming Wang, Li Wei, Junjie Zhang, Aicun Fu
Summary: This study aimed to evaluate the effectiveness of 0.01% atropine eye drops in preventing myopia shift and onset in premyopic children. A 13-month trial was conducted on 60 premyopic children aged 6-12 years. The results showed that 0.01% atropine significantly prevented myopic shift and axial elongation compared to the placebo group. The proportion of myopia onset and fast myopic shift was also significantly lower in the 0.01% atropine group. The study concludes that 0.01% atropine eye drops effectively prevent myopia shift, axial elongation, and myopia onset in premyopic children.
EUROPEAN JOURNAL OF PEDIATRICS
(2023)
Article
Ophthalmology
James Loughman, Emmanuel Kobia-Acquah, Gareth Lingham, John Butler, Ekaterina Loskutova, David A. Mackey, Samantha S. Y. Lee, Daniel I. Flitcroft
Summary: The study investigates the efficacy and safety of 0.01% atropine eye drops in managing myopia progression in a predominantly White, European population. The results show that atropine is effective in slowing axial elongation and is well-tolerated in this population. However, treatment efficacy varies by ethnicity and degree of COVID-19 restriction exposure.
ACTA OPHTHALMOLOGICA
(2023)
Review
Medicine, General & Internal
Yan Yu, Jiasu Liu
Summary: This meta-analysis demonstrates that 0.01% atropine combined with orthokeratology is effective in slowing axial elongation in myopic children, with statistical significance. Subgroup analysis also supports this finding, showing that the combined treatment results in significantly less axial elongation compared to orthokeratology alone. No evidence of publication bias was found.
Review
Medicine, General & Internal
Yue Gao, Yan Yu
Summary: This study aimed to investigate the effect of 0.01% atropine on ocular axial elongation in myopic children. The meta-analysis found that the combination of orthokeratology and 0.01% atropine can effectively control myopia progression, providing helpful evidence for its effectiveness.
Article
Health Care Sciences & Services
Anders Hvid-Hansen, Nina Jacobsen, Flemming Moller, Toke Bek, Brice Ozenne, Line Kessel
Summary: The effect and safety of low-dose atropine in myopia control have been investigated in a European population and the results showed that it is effective and safe, with comparable results to those observed in East Asia, indicating its generalizability across populations with different racial backgrounds.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Ophthalmology
Snigdha Sen, Himanshu Yadav, Anu Jain, Sadhna Verma, Preeti Gupta
Summary: This study aimed to investigate the effect of atropine 0.01% eye drops on myopia progression in children aged over 5 years. The results showed a significant difference in axial length and refraction increase between the treatment and placebo groups after a two-year follow-up.
INDIAN JOURNAL OF OPHTHALMOLOGY
(2022)